Indoxyl sulfate (IS) is a typical uremic toxin that extensively accumulates in the plasma of patients with seriously impaired renal function. This study seeks to clarify whether IS exerts a potent modulating effect on the hepatic transport of pravastatin, which is a substrate of both organic anion transporting peptides (OATPs) and multidrug resistance-associated protein (Mrp) 2 in rats. When IS is administered intravenously to the normal rats at a dose of 120 µmol/kg; plasma IS levels are approximately 600 µM after 2 min and 100 µM after 120 min. In rats with acute renal failure (ARF) induced by cisplatin, the area under the curve (AUC) was more than 2.5-fold greater compared with that in the normal rats, indicating that IS accumulates in ARF rats. Intravenously administered pravastatin almost disappeared from the plasma by 60 min post-administration and approximately 55% of dose was excreted in the bile within 60 min. This result suggested that pravastatin was efficiently taken up from the sinusoid into hepatocytes via rat OATPs on the sinusoidal membrane and preferentially transported in the bile mediated by Mrp2 on the canalicular membrane. IS administered intravenously at a dose of 120 µmol/kg caused neither an increase in plasma pravastatin levels nor a decrease in its biliary excretion. In conclusion, the present results demonstrate that single intravenous administration of IS does not interfere with the hepatic transport of pravastatin directly in vivo, which is at variance with the results of previous in vitro studies.
Introduction
It is generally understood that under seriously impaired renal function a variety of uremic toxins accumulate in the body at greater plasma levels, with indoxyl sulfate (IS) typical of such uremic toxins [1] . Elevated IS levels leads to the induction of various unfavorable events such as progression to renal failure, and cardiovascular and bone toxicities [2] [3] . IS accumulation is attributed primarily to the fact that IS is a potent substrate of organic anion transporter (OAT) and OAT3 presents on the basal membrane of the renal epithelial cells [4] [5] . It was reported previously that, after intravenous administration, IS was eliminated from the rat plasma much faster than other anionic uremic compounds, such as hippuric acid, 3-carboxy-4-methyl-5-propyl-2-furanopropanoic acid, and indole-3-acetic acid [6] , implying a greater involvement of OATs in the elimination of IS via the renal secretory system. Moreover, IS is a highly protein-bound compound. Based on these characteristics, IS is considered to be associated with the occurrence of clinically relevant pharmacokinetic drug interactions in the patients with impaired renal function.
There has been a good deal of interest in the alteration of nonrenal drug clearance in patients with severe chronic kidney disease (CKD) [7] . In this context, the modulating effects of uremic toxins on drug metabolism and transport have been emphasized [ [14] . On the other hand, it is known that the adverse events, such as myopathy and rhabdomyolysis, induced by statins occur preferentially in the patients with seriously impaired renal function. If IS directly interferes with OATP-mediated statin transport in such patients, it is likely that elevated IS levels in patient plasma are responsible for the adverse events induced by statins. In order to assess this, we investigated whether intravenously administered IS can modulate the hepatic transport of pravastatin in normal rats in vivo.
Materials and Methods

Materials
IS and pravastatin sodium were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cisplatin was obtained from Nichi-Iko Pharm. Co. (Toyama, Japan). All other regents were of the highest grade available.
Administration of IS and Pravastatin to Rats
In this study, principles of good laboratory animal care were followed and ani- IS was dissolved in saline at a concentration of 11.5 mM or 60 mM, and pravastatin was dissolved in a mixture of polyethylene glycol 400 and saline (1:1) at a concentration of 1 mM. Following cannulation with a polyethylene tube into the bile duct, IS and pravastatin were administered into jugular vein. The doses of IS administered were 23 µmol/kg or 120 µmol/kg, and that of pravastatin was 2 µmol/kg. In this experiment, IS was administered 5 min prior to pravastatin administration. Two doses of IS were based on our preliminary studywhich investigated IS levels in CKD and hemodialysis patients. Blood (0.4 mL) was drawn at 2, 5, 10 20, 30, and 60 min after administration and plasma samples were kept at -30˚C until assay. The bile was collected at 30-minute intervals. ARF rats were induced by the intraperitoneal administration of cisplatin (5 mg/kg) and used after 3 days following confirmation of elevated serum creatinine levels.
HPLC Analysis
After deproteinization with methanol, IS and pravastatin levels in the plasma were assayed using a Shimadzu LC-10A HPLC system (Kyoto, Japan) equipped with a Shimadzu SPD-10 UV spectrophotometer. Chromatographic conditions were as follows: column, Cosmosil 5C18-AR (i. 
Data Analysis
The AUC was calculated using the trapezoidal method. Data are expressed as the mean with SD of 3 to 4 experiments. Statistical analyses were performed using ANOVA, Dunnett test and Student's t-test, with p < 0.05 considered to be significant.
Results
Plasma IS Levels after Intravenous Administration to Normal and Acute Renal Failure (ARF) Rats
First, we investigated the time course of plasma IS levels after intravenous administration to rats with normal renal function at two doses. At the first sampling time point (2 min), plasma IS levels were approximately 600 and 200 µM after administration at the doses of 23 µmol/kg and 120 µmol/kg, respectively (Figure 1(a) ). While plasma IS almost completely disappeared after 60 min at a 
Effect of IS on the Plasma Levels of Pravastatin in Normal Rats
Next, we evaluated the effect of IS on the clearance of pravastatin from rat plasma after intravenous administration. Pravastatin is partially excreted in the urine after oral administration in humans [17] , with OATs known to be involved in the process [18] . Therefore, in this study, we used normal rats in order to exclude the impact of impaired renal function on the elimination of pravastatin. As shown in Figure 2 , the plasma levels of pravastatin declined very sharply and 
Effect of IS on the Biliary Excretion of Pravastatin in Normal Rats
The biliary excretion of pravastatin is shown in Figure 3 . When pravastatin was intravenously administered alone, approximately 55% of the dose appeared in The unit for the AUC was μmol·min/ml. 
Discussion
The results of this study showed that intravenously administered pravastatin disappeared very quickly from the plasma in normal rats ( Figure 2 ) and that more than 50% of the pravastatin was excreted in the bile within first 60 min post-administration (Figure 3) . Moreover, the biliary excretion of pravastatin ended when it had almost completely disappeared from the plasma. These results strongly suggested that pravastatin was taken up very efficiently from the sinusoid into hepatocytes and then transported into the bile across the canalicular membranes.
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